Summary

The 7 major abdominal aortic aneurysm markets reached a value of US$ 1,692.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,235.2 Million by 2034, exhibiting a growth rate (CAGR) of 6.07% during 2024-2034.

The abdominal aortic aneurysm market has been comprehensively analyzed in IMARC's new report titled "Abdominal Aortic Aneurysm Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". An abdominal aortic aneurysm (AAA) refers to a condition where a section of the aorta becomes enlarged and weakened, causing it to bulge outward. It is most commonly found in the lower part of the aorta in the abdomen and can grow over time, increasing the risk of rupture and life-threatening bleeding. In most cases, abdominal aortic aneurysms do not cause any symptoms, and they are often discovered incidentally during routine medical exams or imaging tests done for other reasons. However, some people with AAAs may experience various symptoms, such as constant pain in the abdomen, a pulsating feeling near the navel, back pain, leg pain, etc. These indications may be more common if the aneurysm is growing rapidly or pressing on nearby organs or nerves. The disorder can be diagnosed through a physical examination, several imaging tests, and blood tests. During the physical exam, a pulsating mass in the abdomen can indicate the presence of an AAA. Various imaging tests, including ultrasound, CT scan, MRI, etc., can confirm the diagnosis and provide information about the size, location, and shape of the aneurysm. Additionally, blood tests can also help diagnose AAA by measuring levels of specific proteins associated with the condition.

The increasing prevalence of atherosclerosis and infectious aortitis is primarily driving the abdominal aortic aneurysm market. Furthermore, the inflating cases of several associated risk factors, such as genetic disorders of connective tissue and congenital syndromes, are also augmenting the market growth. In addition to this, the escalating utilization of effective drugs, including beta-blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, etc., for managing AAA-related complications, such as hypertension and atherosclerosis, is creating a positive outlook for the market. Moreover, the emerging popularity of endovascular aneurysm repair (EVAR), a minimally invasive approach, on account of its numerous advantages over open surgery, including shorter hospital stays, faster recovery times, and reduced risk of complications, is also bolstering the market. Apart from this, several key players are making extensive investments in developing drugs that prevent or delay the progression of AAA, which could potentially lower the need for surgical interventions. This, in turn, is acting as another significant growth-inducing factor. Additionally, the introduction of new endovascular devices, such as branched and fenestrated stent grafts, to treat complex AAA cases is further propelling the market growth. These devices can be custom-made to fit patient's specific anatomy and can reduce the requirement for open surgery. Besides this, the widespread adoption of hybrid procedures, which combine surgery and endovascular repair, and offer a tailored approach to AAA treatment for patients with complex anatomies or high-risk factors, is expected to drive the abdominal aortic aneurysm market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the abdominal aortic aneurysm market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for abdominal aortic aneurysm and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the abdominal aortic aneurysm market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the abdominal aortic aneurysm market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the abdominal aortic aneurysm market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current abdominal aortic aneurysm marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights

How has the abdominal aortic aneurysm market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the abdominal aortic aneurysm market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the abdominal aortic aneurysm market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm across the seven major markets?
What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of abdominal aortic aneurysm by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with abdominal aortic aneurysm across the seven major markets?
What is the size of the abdominal aortic aneurysm patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of abdominal aortic aneurysm?
What will be the growth rate of patients across the seven major markets?

Abdominal Aortic Aneurysm: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for abdominal aortic aneurysm drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the abdominal aortic aneurysm market?
What are the key regulatory events related to the abdominal aortic aneurysm market?
What is the structure of clinical trial landscape by status related to the abdominal aortic aneurysm market?
What is the structure of clinical trial landscape by phase related to the abdominal aortic aneurysm market?
What is the structure of clinical trial landscape by route of administration related to the abdominal aortic aneurysm market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Abdominal Aortic Aneurysm - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Abdominal Aortic Aneurysm - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Abdominal Aortic Aneurysm - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Abdominal Aortic Aneurysm - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Abdominal Aortic Aneurysm - Unmet Needs

10 Abdominal Aortic Aneurysm - Key Endpoints of Treatment

11 Abdominal Aortic Aneurysm - Marketed Products
11.1 List of Abdominal Aortic Aneurysm Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Abdominal Aortic Aneurysm - Pipeline Drugs
12.1 List of Abdominal Aortic Aneurysm Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. Abdominal Aortic Aneurysm - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Abdominal Aortic Aneurysm – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Abdominal Aortic Aneurysm - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Abdominal Aortic Aneurysm - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Abdominal Aortic Aneurysm - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Abdominal Aortic Aneurysm - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Abdominal Aortic Aneurysm - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Abdominal Aortic Aneurysm - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Abdominal Aortic Aneurysm - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Abdominal Aortic Aneurysm - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Abdominal Aortic Aneurysm - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Abdominal Aortic Aneurysm - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Abdominal Aortic Aneurysm - Access and Reimbursement Overview

16 Abdominal Aortic Aneurysm - Recent Events and Inputs From Key Opinion Leaders

17 Abdominal Aortic Aneurysm Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Abdominal Aortic Aneurysm Market – Strategic Recommendations

19 Appendix